EXPO CATALOGUE

Friday 12 June - Sunday 14 June
Sydney Convention & Exhibition Centre
Darling Harbour, Sydney

EARN UP TO
20 CPD POINTS

www.pharmacyexpo.com.au

The Pharmacy Guild of Australia
Pharmaceutical Society of Australia
FRIDAY 12 JUNE

CLINICAL FOCUS RED (Cardiovascular) - Theatre 4

11.00am - 12.30pm
MANAGEMENT OF DYSPILIDAEMIA

Cardiovascular disease (CVD) is a leading cause of death in Australia. In addition to age and gender, raised cholesterol, raised blood pressure and smoking are three modifiable risk factors for CVD. Modification of lipid levels is therefore a key strategy for reducing overall cardiovascular risk. This presentation will provide an overview of current guidelines for lipid management as well as the interpretation and application of various clinical laboratory data such as LDL-C, HDL-C, TG and apolipoproteins. Evidence for the management of dyslipidaemia, both pharmacological and non-pharmacological, will be covered.

DR TIMOTHY CHEN - BPharm, DipHPPharm, PhD, MPS
Senior lecturer in Pharmacy Practice, University of Sydney
Dr Chen's main teaching and research interests focus on the role of the pharmacist in conducting Home Medicine Reviews in collaboration with general medical practitioners. He has also conducted several research projects in the area of mental health. In 2001, Dr Chen was awarded the Young Pharmacist of the Year Excellence Award by the Pharmaceutical Society of Australia for his contribution to research and professional training in the field of medication review and interprofessional collaboration. Dr Chen has conducted numerous seminars for pharmacists and medical practitioners over the last five years. He has also been an invited plenary speaker at many national and international conferences.

1.30am - 3.00pm
ANTITHROMBOTICS: HOW PHARMACISTS CAN OPTIMISE OUTCOMES

Antithrombotic agents (anticoagulant and antiplatelet drugs) are some of the most commonly dispensed medications in community pharmacies. However, antithrombotics are also frequently associated with adverse drug reactions. It is common to see antithrombotics used in various combinations, and in the elderly, which further increases the risk of adverse events. This session will provide some context to the appropriate use of antithrombotic agents available including some background into thrombosis and its consequences, the rationale for pharmacotherapy, appropriate drug choice and the importance of clinical monitoring. Dr Bereznicki will discuss in detail the research he is undertaking into the optimisation of warfarin management, including new models of care, patient education and transitional care. He will also discuss how this research might be implemented in community pharmacy in the future.

DR LUKE BEREZNICKI - BPharm (Hons) MPS, AACPAd, PhD
Senior Research Fellow/Lecturer in Pharmacy Practice, UMORE, School of Pharmacy, University of Tasmania
Dr Bereznicki is currently a lecturer at the Tasmanian School of Pharmacy. He is part of a pharmacy-practice research group, UMORE, and writes for the Australian Pharmacist. His major research focus has been on improving the use of anticoagulant drugs in the community. This work has involved the implementation and evaluation of pharmacist involvement in a variety of quality improvement activities in the hospital and community settings. A key aspect of this work involved the development of patient education materials for warfarin therapy and the implementation of a model of care involving patient home monitoring of warfarin therapy with electronic communication of results to other health professionals.

Luke is currently a lead investigator on two projects funded through the Fourth Pharmacy Guild-Government Agreement, which aim to evaluate the role of pharmacists in providing education, support and ongoing monitoring for people taking warfarin in the community. He is also a practicing pharmacist and regularly works in retail pharmacy. Luke was the PSA Young Pharmacist of the Year in 2008.

3.30pm - 5.00pm
HYPERTENSION – NHF GUIDELINES & PERSISTENCE AND ADHERENCE TO THERAPY

In 2008 the National Heart Foundation released an updated version of their Guide to the management of hypertension which incorporates the latest evidence and recommendations from international guidelines. The guide makes several recommendations that change how hypertension is diagnosed and managed. In this session Professor Carol Pollock will outline the key recommendations of the updated guide and will draw upon her extensive experience to provide some clinical context to the changes. Following this, Dr Michael Ortiz will explain how patient compliance to antihypertensive therapy is less than satisfactory in the Australian community. He will present the key findings of his recent research in this area and will explore how pharmacists can play an important role in ensuring better persistence and adherence to antihypertensive therapies.